Anticoagulation Selection for Atrial Fibrillation Patients

Patient Classification and Risk Assessment

The American College of Cardiology recommends calculating the CHA₂DS₂-VASc score to assess stroke risk in patients with non-valvular atrial fibrillation 1, 2
Anticoagulation is recommended for all AF patients except those with lone AF (no risk factors) or contraindications to anticoagulation, as stated by the American College of Cardiology 3, 4

The American College of Cardiology recommends direct oral anticoagulants (dabigatran, rivaroxaban, apixaban, or edoxaban) as first-line therapy for non-valvular AF patients due to their superior safety profile and at least equivalent efficacy for stroke prevention 1, 5, 2
For apixaban, a dose adjustment to 2.5 mg twice daily is recommended if the patient has ≥2 of the following: age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL, according to the American College of Cardiology 6
Warfarin is the only recommended anticoagulant for patients with mechanical heart valves or moderate to severe mitral stenosis, with a target INR of 2.5-3.5 depending on valve type and position, as recommended by the American College of Cardiology 1, 5, 2, 4

For patients on warfarin, the American College of Cardiology recommends checking INR at least weekly during initiation and once stable, checking INR monthly 3, 4
For patients on DOACs, regular assessment of renal function and periodic reassessment of bleeding risk are recommended by the American College of Cardiology 5, 6

Elderly patients (≥75 years) have a higher bleeding risk but also a higher stroke risk, making anticoagulation particularly beneficial, according to the American College of Cardiology 4, 7
Patients with prior stroke or TIA are at the highest risk and derive the greatest benefit from anticoagulation, as stated by the American College of Cardiology 4, 7

Underdosing DOACs in high-risk patients due to bleeding concerns increases stroke risk without proven safety benefit, as warned by the American College of Cardiology 6
Using aspirin alone in moderate to high-risk patients is substantially less effective than anticoagulation for stroke prevention, according to the American College of Cardiology 4, 7
Failing to reassess anticoagulation needs and bleeding risk periodically is a common pitfall, as noted by the American College of Cardiology 5
Inappropriate discontinuation of anticoagulation before procedures can be avoided, as many procedures can be performed safely without interrupting anticoagulation, as recommended by the American College of Cardiology 3

The European Society of Cardiology recommends direct oral anticoagulants (DOACs) as first-line therapy over warfarin for stroke prevention in patients with non-valvular atrial fibrillation, due to their superior safety profile and at least equivalent efficacy for stroke prevention compared to vitamin K antagonists 8

The American College of Cardiology recommends warfarin for patients with moderate-to-severe rheumatic mitral stenosis, with a target INR of 2.0-3.0 9

The American College of Cardiology recommends INR monitoring weekly during warfarin initiation and monthly once stable, with a target INR of 2.0-3.0 for most AF patients 9, 10

The European Society of Cardiology recommends therapeutic anticoagulation for ≥3 weeks before cardioversion and ≥4 weeks after, with long-term continuation based on stroke risk factors, and prefers DOACs over warfarin due to superior safety and equivalent efficacy 8

The European Society of Cardiology advises against using bleeding risk scores to withhold anticoagulation in patients with stroke risk factors, as this leads to underuse of life-saving therapy 8
The European Society of Cardiology advises against switching between DOACs or from DOAC to warfarin without clear clinical indication, such as recurrent thromboembolism, intolerance, or renal deterioration 8

Patients with moderate to high stroke risk (CHA₂DS₂-VASc score ≥2 in men or ≥3 in women) should receive anticoagulation regardless of left atrial size, as recommended by the American Family Physician 11, 12

Direct oral anticoagulants (DOACs)—apixaban, rivaroxaban, dabigatran, or edoxaban—are recommended as first-line therapy over warfarin for non-valvular AF, according to the American College of Chest Physicians 13
Apixaban 5 mg twice daily ranks highest for most efficacy and safety outcomes, and demonstrates superiority over warfarin in preventing stroke or systemic embolism (hazard ratio 0.79, 95% CI 0.66-0.94), with significantly less major bleeding, as reported by the American College of Chest Physicians 13

Warfarin reduces stroke risk by 39% compared to antiplatelet therapy, and should be used instead of aspirin alone in moderate to high-risk patients, as recommended by the American College of Chest Physicians 13
A high HAS-BLED score (≥3) is rarely a reason to avoid anticoagulation; instead, address modifiable bleeding risk factors, according to the American College of Chest Physicians 13

A mitral annuloplasty ring is NOT a mechanical prosthetic valve and does not fall under the "valvular AF" category that mandates warfarin therapy, as stated by the European Society of Cardiology 14, 15
Patients with mitral valve repair (including annuloplasty rings) and AF should be treated according to standard non-valvular AF anticoagulation guidelines, as recommended by the European Society of Cardiology 14, 15

DOACs (apixaban, rivaroxaban, dabigatran, or edoxaban) are recommended as first-line therapy for patients with AF and mitral annuloplasty rings, according to the European Society of Cardiology 14, 15
Continuation of oral anticoagulation is mandatory according to the patient's CHA₂DS₂-VASc score, not based on the presence of the annuloplasty ring or perceived success of any rhythm control procedures, as stated by the European Society of Cardiology 14, 15

If DOACs are contraindicated or not tolerated, warfarin with a target INR of 2.0-3.0 is appropriate, as recommended by the American College of Cardiology 16
INR monitoring should be performed at least weekly during initiation and monthly once stable in the therapeutic range, according to the American College of Cardiology and the American Geriatrics Society 16, 17

After mitral valve repair surgery with concomitant AF ablation, anticoagulation must continue for at least 2 months post-procedure in all patients, regardless of rhythm outcome, as stated by the European Society of Cardiology 14, 15
Long-term anticoagulation decisions after this initial period should be based solely on CHA₂DS₂-VASc score, independent of rhythm outcome or left atrial appendage exclusion, according to the European Society of Cardiology 14, 15